Training Course in Sexual and Reproductive Health Research Geneva 2016

How to use WHO's family planning guidelines and tools

Mary Lyn Gaffield, Human Reproduction Team, World Health Organization





Learning objectives

- To understand the purpose of WHO's family guidelines and tools.
- To be able to identify and apply medical eligibility criteria and practice recommendations for family planning service delivery.

To know how to use family planning tools for service provision.



The need for evidence-based guidance

- To base family planning practices on the best available published evidence
- To address misconceptions regarding who can safely use contraception
- To reduce medical barriers
- To improve access and quality of care in family planning



WHO guidelines and tools

Medical Eligibility Criteria Selected Practice Recommendations







The 2015
Medical
Eligibility
Criteria Wheel



(ii) remain

MEDICAL ELIGIBLITY CRITERIA WHEEL FOR CONTRACEPTIVE USE




5th edition just published!







Global Handbook




Reproductive Choices and Family Planning for People with HIV



Guide to family planning for health care providers and their clients



Medical eligibility criteria for contraceptive use (MEC)



Purpose: Who can safely use contraceptive methods?

- First published in 1996, revised
 through expert meetings held in 2000,
 2003, 2008 and 2014
- □ Fifth edition offers ≈ 2000 recommendations for 25 methods
- Available in English; available soon in French, Spanish, and Portuguese.
 WHO will facilitate other language translations.

MEC Categories

1	A condition for which there is no restriction for the use of the contraceptive method
2	A condition where the advantages of using the method generally outweigh the theoretical or proven risks
3	A condition where the theoretical or proven risks usually outweigh the advantages of using the method
4	A condition which represents an unacceptable health risk if the contraceptive method is used

Where warranted, recommendations will differ if a woman is starting a method (I = initiation) or continuing a method (C = continuation)

CATEGORY	WITH CLINICAL JUDGEMENT	WITH LIMITED CLINICAL JUDGEMENT		
1	Use method in any circumstances	Yes		
2	Generally use the method	(Use the method)		
3	Use of method not usually recommended unless other more appropriate methods are not available or not acceptable	No (Do not use the method)		
4	Method not to be used			



Classification of recommendations - female and male surgical sterilization

- Divided into four categories:
 - Accept 'A' = There is no medical reason to deny sterilization to a person with this condition,
 - Caution 'C' = The procedure is normally conduced in a routine setting, but with extra preparation and precautions,
 - Delay 'D' = The procedure is delayed until the condition is evaluated and or corrected. Alternative temporary methods of contraception should be provided,
 - Special 'S' = The procedure should be undertaken in a setting with an experienced surgeon and staff, equipment needed to provide general anaesthesia, and other back-up medical support. The capacity to decide the most appropriate procedure and anaesthesia regimen is needed. Alternative temporary methods of contraception should be provided, if referral is required or there is otherwise any delay.



Clarifications

- Clarification of the classification, in cases where the number itself does not adequately communicate the essence of the recommendation
 - Appears in the right hand column of the MEC document
 - Responsibility of guideline development group



Presentation of recommendations: an example

SUMMARY TABLE								
	COC//P/CVR	CIC	POP	DMPA/NET-EN	LNG/ETG/ IMPLANTS	CU-IUD	LNG-IUD	
OBESITY								
a) \geq 30 kg/m ² BMI	2	2	1	1	1	1	1	
b) Menarche to < 18 years and ≥ 30 kg/m ² BMI	2	2	1	2ª	1	1	1	

Source: Medical Eligibility Criteria for Contraceptive Use. WHO:

Geneva, 2015.



Presentation of recommendations – another example

SUMMARY TABLE								
	COC//P/CVR	CIC	POP	DMPA/NET-EN	LNG/ETG/ IMPLANTS	CU-IUD	LNG-IUD	
ENDOCRINE CONDITIONS								
DIABETES								
a) History of gestational disease	1	1	1	1.	1	1	1	
b) Non-vascular disease								
i) non-insulin-dependent	2	2	2	2	2	1	2	
ii) insulin-dependent	2	2	2	2	2	1	2	
c) Nephropathy/retinopathy/ neuropathy	3/4 ^a	3/4 ^a	2	3	2	1	2	
d) Other vascular disease or diabetes of > 20 years' duration	3/4 ^a	3/4 ^a	2	3	2	1	2	

Source: Medical Eligibility Criteria for Contraceptive Use. WHO: Geneva, 2015.



Case study: which methods can be used?

- □ A 24 year old woman with a body mass index greater than 30 kg/m²?
 - COC ?
 - IUD?
 - Injectable ?
 - Implants ?

- A 38 year old woman who with diabetes for more than 20 years?
 - COC ?
 - IUD?
 - Implants ?
 - Injectable ?





WHO



MEDICAL ELIGIBILITY CRITERIA WHEEL FOR CONTRACEPTIVE USE 2015







MEC Wheel

- Offers accessible MEC guidance for most commonly encountered medical conditions.
- Recommendations available numerous methods
 - Combined methods (pills, the patch, the vaginal ring, combined injectable)
 - Progestogen-only methods (injectable [DMPA IM & subcutanesou, NET-EN], implants, pills)
 - Copper-bearing IUD
 - LNG-releasing IUD
- Conditions that are either '1' or '2', appear on back of wheel.
- Additional explanations for certain recommendations apear on the back of wheel
- Locate condition of interest, then turn wheel to identify eligibility category.



- A If condition develops while using method, can continue using it during treatment.
- B If very high likelihood of exposure to gonorrhoea or chlamydia =3.
- C If past pelvic inflammatory disease (PID) all methods =1, including IUDs.
- D If <3 wks, not breastfeeding & no other VTE risk factors =3.</p>
- E If not breastfeeding =1.
- If 3 to <6 wks, not breastfeeding & no other VTE risk factors =2, with other VTE risk factors =3.
- G If ≥6 wks & not breastfeeding =1.
- H If uterine cavity distorted preventing insertion =4.
- Refers to hepatocellular adenoma (benign) or carcinoma/ hepatoma (malignant).
- J If adenoma CIC =3, if carcinoma/hepatoma CIC =3/4.
- K CIC =3.
- L If established on anticoagulation therapy =2.
- M If condition developed while on this method, consider switching to non-hormonal method.
- N Risk factors: older age, smoking, diabetes, hypertension, obesity & known dyslipidaemias.
- 0 If cannot measure blood pressure & no known history of hypertension, can use all methods. Either systolic or diastolic blood pressure may be elevated.
- P If age <18 yrs & obese DMPA/NET-EN =2.
- Q For insulin-dependent & non-insulin-dependent. If complicated or >20 yrs duration, COC/P/CVR, CIC =3/4; DMPA. NET-EN =3.

- R If <15 cigarettes/day CIC =2. If ≥15 cigarettes/day COC/P/CVR =4.
- S Aura is focal neurological symptoms, such as flickering lights. If no aura & age <35 COC/P/CVR, CIC =2, POP =1. If no aura & age ≥35 COC/P/CVR, CIC =3, POP =1.
- T Barbituates, carbamazepine, oxcarbazepine, phenytoin, primidone, topiramate & lamotrigine.
- U If barbituates, carbamazepine, oxcarbazepine, phenytoin, primidone or topiramate CIC =2.
- V If lamotrigine =1.
- W DMPA =1, NET-EN =2.
- X CICs =2.
- Y If antiretroviral therapy with EFV, NVP, ATV/r, LPV/r, DRV/r, RTV: COC/P/CVR, CIC, POP, NET-ET, Implants =2; DMPA =1. For all NRTIs, ETR, RPV, RAL each method =1. See lacket for full names of medications.
- Z If WHO Stage 3 or 4 (severe or advanced HIV clinical disease) IUD =3.

Conditions that are category 1 and 2 for all methods (method can be used)

Reproductive Conditions: Benign breast disease or undiagnosed mass . Benign ovarian tumours, including cysts . Dysmenorrhoea . Endometriosis . History of gestational diabetes . History of high blood pressure during pregnancy . History of pelvic surgery, including caesarean delivery . Irregular, heavy or prolonged menstrual bleeding (explained) • Past ectopic pregnancy • Past pelvic inflammatory disease • Post-abortion (no sepsis) • Postpartum ≥ 6 months

Medical Conditions: Depression • Epilepsy • HIV asymptomatic or mild clinical disease (WHO Stage 1 or 2) • Iron-deficiency anaemia, sickle-cell disease and thalassaemia • Malaria • Mild cirrhosis • Schistosomiasis (bilharzia) • Superficial venous disorders, including varicose veins • Thyroid disorders Tuberculosis (non-pelvic) • Uncomplicated valvular heart disease • Viral hepatitis (carrier or chronic)

> Other: Adolescents . Breast cancer family history . Venous thromboembolism (VTE) family history . High risk for HIV Surgery without prolonged immobilization
> Taking antibiotics (excluding rifampicin/rifabutin)

With few exceptions, all women can safely use emergency contraception, barrier and behavioural methods of contraception, including lactational amenorrhoea method; for the complete list of recommendations, please see the full document.

"Combined" is a combination of ethinyl estradiol & a progestogen.

CIC: combined injectable contraceptive COC: combined oral contraceptive pill Cu-IUD: copper intrauterine device CVR: combined contraceptive vaginal ring DMPA (IM, SC): depot medroxyprogesterone acetate, intramuscular or subcutaneous ETG: etonogestrel LNG: levonorgestrel LNG-IUD: levonorgestrel intrauterine device NET-EN: norethisterone enanthate P: combined contraceptive patch POP: progestogen-only pill





Selected practice recommendations for contraceptive use



Purpose: How to safely deliver contraceptive methods?

 First published in 2000, revised through expert meetings held in 2004 and 2008

Second edition offers 33 practice recommendations

Available in English, French, Spanish, Arabic, Chinese, Romanian, Portuguese, Russian, Vietnamese, Sri Lankan

Practice questions

Examples:

- when to start
- when to re-administer
- how to manage problems
 - missed pills
 - bleeding (progestogen-only methods and IUDs)
 - prophylactic antibiotics and IUD insertion
- what examinations and tests are required before starting a method



When can a woman start combined oral contraceptives (COCs)?

Note: The woman may be provided with COCs in advance with appropriate instructions on pill initiation, provided she is medically eligible.

Having menstrual cycles

- She can start COCs within 5 days after the start of her menstrual bleeding. No additional contraceptive protection is needed.
- She also can start COCs at any other time, if it is reasonably certain that she is not pregnant.
 If it has been more than 5 days since menstrual bleeding started, she will need to abstain from sex or use additional contraceptive protection for the next 7 days.

Amenorrhoeic

She can start COCs at any time, if it is reasonably certain that she is not pregnant.
 She will need to abstain from sex or use additional contraceptive protection for the next 7 days.


Postpartum (breastfeeding)*

- If she is more than 6 months postpartum and amenorrhoeic, she can start COCs as advised for other amenorrhoeic women.
- If she is more than 6 months postpartum and her menstrual cycles have returned, she can start COCs as advised for other women having menstrual cycles.
- * Additional guidance from the Medical eligibility criteria for contraceptive use. Third edition, 2004. Women less than 6 weeks postpartum who are primarily breastfeeding should not use COCs. For women who are more than 6 weeks but less than 6 months postpartum and are primarily breastfeeding, use of COCs is not usually recommended unless other more appropriate methods are not available or not acceptable.

Postpartum (non-breastfeeding)*

 If her menstrual cycles have not returned and she is 21 or more days postpartum, she can start COCs immediately, if it is reasonably certain that she is not pregnant. She will need to abstain from sex or use additional contraceptive protection for the next 7 days.







Routine exams or tests

Exam or screening	Hormonal methods	IUD	Condoms / Spermicide	Female sterilization
Breast exam	С	С	С	С
Pelvic exam	С	Α	С	Α
Cervical cancer	С	С	С	С
Routine lab tests	С	С	С	С
Hemoglobin	С	В	С	В
STI risk assessment	С	Α	С	С
STI screening	С	В	С	С
Blood pressure	**	С	С	Α

Class A: essential and mandatory in all circumstances

Class B: contributes substantially to safe and effective use

Class C: does not contribute substantially to safe and effective use




Decision-making tool for family planning clients and providers



- A tool for providers and their clients. Contains evidencebased technical information
- Contains evidence-based technical information and a counseling process
- To be used with clients in the clinic
- Uses simple language
- Illustrations for clients





Improved counseling has the potential to:


Increase:

- Client satisfaction
- Provider satisfaction
- Correct use of methods
- Continuation of use

Reduce:

- Dropout from services
- Unnecessary health risks
- Method failure
- Unwanted pregnancy













A structured counselling process



Main points on a CLIENT PAGE


Most important points for client



Decision-making question: client needs to respond and participate before going to next page



Main points on a PROVIDER PAGE



Counseling Icons







Offer support




Check understanding




Listen carefully

Choosing a method



Choosing a method:

Do you have a method in mind?



If you do, let's talk about how well it suits your needs

- · What have you heard about it?
- · What do you like about it?

If not, we can find a method right for you



Important for choosing a method:

Do you need protection from pregnancy AND sexually transmitted infections?


- Focus on what she knows about the method
- 2. Check understanding of the method
- 3. Can also discuss other options

Best practices in FP counseling:



1. Focus on needs and situation

Compare methods in light of needs and situation



Dual Protection



Dual Protection = Protection from pregnancy and STIs/HIV



Dual Protection


Do you have a method in mind?



If you do, let's talk about how it suits you

- · What do you like about it?
- What have you heard about it?

If not, we can find a method that is right for you



Do you need protection from sexually transmitted infections (STIs) or HIV/AIDS?

Part of the decision-making process

Comparing methods





More side-effects:





Effective but must be <u>carefully used</u>.



/ Copper IUD


- Small device that fits inside the wornb
- Very effective

Keeps working up to 10 years, depending on type

- We can remove it for you whenever you want
- Very safe
- Might increase menstrual bleeding or cramps
- No protection against STIs or HIV/AIDS



Do you want to know more about the IUD, or talk about a different method?



Special Needs

Special needs

Clients with special needs

These pages help clients who may need special counselling or advice.

- Younger client......go to next page (page SN2)
- Older client......go to page SN3
- Pregnant/postpartum client.....go to page SN4
- Post-abortion client......go to page SN5
- Client living with HIV/AIDS......go to page SN6
- Client who wants to become pregnant....go to page SN7

Next Move:

Go to correct page in this section.








Returning Clients


What method are you using? Returning Client Vasectomy or IUD.....next page **Female Sterilization**page RC 14 The Pill.....page RC 4 Condoms (male or female).....page RC 15 The Mini-Pill.....page RC 6 Vaginal Methods.....page RC 17 Long-Acting Injectable.....page RC 8 LAM.....page RC 19 Monthly Injectable.....page RC 10 Fertility Awareness-Based Methods.....page RC 21 Implants.....page RC 12 **Next Move:** Go to the correct page to help returning client.








Returning Clients




Find the right page in the section (no tabs)



Managing problems



Method Sections





Who can and cannot use the pill

Most women can safely use the pill



Medical eligibility criteria in the method section

But usually cannot use the pill if:



age 35 or

older

Smoke High blood pressure



 Gave birth in the last 3 weeks



Breastfeeding 6 months or less



May be pregnant



conditions

For other less common conditions, need to check on providers page



Who can and cannot use the pill

Most women can safely use the pill. But usually cannot use the pill if:

- Smoke cigarettes AND age 35 or older
- High blood pressure
- Gave birth in the last 3 weeks
- Breastfeeding 6 months or less
- May be pregnant
- Some other serious health conditions:

Usually cannot use with any of these serious health conditions (if in doubt, check handbook or refer)



454

Sentargia a migraine?

Asic: Co you often have very painful headaches, perhaps on one side orthobbling, that cause nausea and are made worse by light and noise or moving about?*

Next Move:

Client able to use the pill: go to next page. "We can find out if the pill is safe for you. Usually, women with any of these conditions should use another method."


- Check blood pressure (8P) if possible. If systolic 8P 140+ or disatolic 8P 90+, kep ter choose a notiver me fixed (bit not a monthly litectable). (if systolic 8P 160+ or disatolic 8P 100+, also should not use long-acting injectable).
- If BP check not possible, ask about high BP and rely on her answer.
- If is doubt, use pregnancy checklist in Appendix 1 or perform pregnancy text
- Euer had stroke or problem with heart or blood uessels.
- Migrathe headaches*: sites to tid not use the pill fishe is over 35 and has migrathes, or at any age if her usion, speech or movement is affected by the migrathes. Whome is under 35 who have migrathes without these symptoms, and women with ordinary headaches CAN is vally use the pill.
- Buer had breast cancer.
- Has 2 or more risk factors for heart disease, such as hypertension, diabetes, smokes, or older age.
- Galibladder disease.
- Haseuer had blood cloth lings or deep hilegs. Women with superficial clots (holidhig warlcose behas) CAN use the pill.
- Soon to have surgery? She should not start if she will have surgery
 making her immobile for more than 1 week.
- · Serious iluer disease or jaun dice (yellowiskin or eyes).
- Blabetes for more than 2D years, or severe damage caused by diabetes.
- Takes pills for tuberoulosis, fungal intections, or epileps vise to ures/ffs).

Client unable to use the pill: help her choose another method, but not monthly injectable.


Appendices: extra counseling tools



13 appendices with additiona tools and information for providers







Boermioldes

8: Facts about STIs and HIV/AIDS

What is a se sually transmitted. Testing, counselling, and treatment for Matare HM and AIDS? Infection (STIP HMAIDS HIV (Human in munodericlency Virus) is a virus.

- An STills an infection that can be spread. from person to person by sexual contact.
- Some STB can be transmilled by any sexual act that involves contact be ween. he penis, uagina, anus and/or mouth. For besi protection, a couple thould uce condoms, or avoid any contactin the gent tal area (I noted in g oral and anal cest
- BTI cmay or may no toau ce tymp to mic. Some cause pain, Otten, however, people (particularly women) may not know that they have an STI until a major problem de uslogs.
- Bome common BTI coan be treated and pured with aniibloics. These STk Include gonorhoea, chiamydiai Infection, chancroid and syphilis. Trichomoniasis, while usually not sexually transmitted, also can be lealed.
- Bome cannot be oured, including hepail is 8, genital herpes, human papilloma ulrus (RPV) and RIV (see dahb.
- fra woman has an STI, she is alignealer risk for some reproductive cancers, pelulo Inflammatory disease, eclopic pregnancy, miscardage and HTV infection. Bome Bill coan caute intertility and death, particularly (first treated.

To see who is a risk for 5 Tis, see Dual Promedon ph, page DP2


- that i core centin the blood, body fuld cand in come body coored on a crimecial people. HIV can be transmilled:
- by sexual contact (through semen or uaginal) rivids during penetrative vaginal and analisex, and to a much lesser degree during oral sex);
- brough intected blood, in particular brough shared or relused syringe needles and equipment (either for medical injections or drug use);
- from mother to child during pregnancy or childbirth or through breas i milk.
- HIV IS NOT TRANSMITTED brough he air, by insectibiles, through salius or idssing (as long as here are no cult in the mouth), through louching or hugging, or by sharing food, plates or cups.
- Girls and young women are all particularly high risk of acquiring. HTV during unprojected sexual Intercourse due to social and biological outnerability.
- ALDB (Acquired Immune Deviciency Syndrome) is characterized by certain displayed that develop during the final clage coffthe HIV Intention Of leff uniteated), finesses deuelog because HTV progressively weakens the immune system and reduces the body's ability to right disease (for example, pneumonia, lube roulosis, maiaria, shingles or dianhoea).
- After a person contracts HTV, digit cand cymp to mic oif cloking conformally take many gears to develop.

- · Apercon Holog with Ally usually look cand feels
- healthy. Most people with HTV do not know that hey are carrying the utrus.
- To preuent imedions and to promote access to care and teament, it is important for a person to know higher HIV status
- The only way to tell tria person has HTV is a blood. lest. Blood lests can usually detect HTV 6 weeks after the person has been exposed to the ulrus. Positive les i results need confirmation before diagnosing or counselling the patient.
- Recommend HTV lesting for all clients who may be at risk of acquiring HTV. Testing should always be uoluntary, based on informed consent, and be combined with counselling. Assure client trai all te cit; are o on tide nital.
- When a client learns that he/she has a positive HTV lest result, other counselling and support, including couple counselling. Encourage sexual partners to tell each other their lest results. In his is not risky. Refer as appropriate.
- As of 2005, ALDB hald no definite ours and there. I and vaccine against HIV. However, in come places, free fine of for HIV with an fire free viral drug c may be a valiable. Trealment can significantly enhance quality of the and length of the .
- To preuent mother-to-child transmission of HTV, at wide range of services should be made available for women living with HTV, including family planning seruices, drugs to avoid transmission to the baby, and proper breas feeding adulce and support.

per 300 wemen in ene

year Least effective


Reproductive Choices and Family Planning for People with HIV



- Two-day training and job aid an adaptation of the Decision-Making Tool for Family Planning Clients and Providers
 - Developed as part of Integrated Management of Adolescent and Adult Illness (IMAI) series
- Field tested in Uganda and Lesotho
- Developed in collaboration with the INFO Project at Johns Hopkins Bloomberg School of Public Health
- First edition published in 2006 and available on WHO website




Road map of this counseling tool



Safer sex and living with HIV

- Can still enjoy sexual intimacy
- There are ways to lower risk
- Some sexual activities are safer than others





Do you know your partner's HIV status?



Questions about sexual relationships:

- Does client know the HIV status of sex partner(s)?
- Does partner(s) know client's HIV status?

If a partner's status is unknown:

- Discuss reasons that client's partner(s) should be tested for HIV.
 - Even if you are HIV positive, your partner may not be infected.
 - When both partners know their status, they can then know how best to protect themselves.
- When status is unknown, assume your partner is negative and needs protection from infection. Important to use condoms.

If a partner is HIV negative:

- Explain that it is common for a person who is HIV positive to have a partner who is HIV negative.
- HIV is not transmitted at every exposure, but HIV-negative partners are at a high risk of infection.
- Important to always use condoms or avoid penetrative sex.

If both you and your partner are HIV positive:

- If mutually faithful, the couple may choose not to use condoms and may choose another method for pregnancy protection.
- If not mutually faithful or faithfulness is uncertain, condoms should be used or penetrative sex avoided to prevent STIs.

How to use this page:


- Discuss HIV status of client and partner(s) so they can know how to best protect themselves.
- If client has not disclosed HIV status to partner, discuss benefits and risks of disclosure.
- Help client develop strategy for disclosure, if client is ready.
- Strongly encourage and help with partner testing and counselling.

Next step: Discuss safer sex and living with HIV (go to next page).

Preparing to disclose HIV status

- · Who to tell?
- · When to tell?
- · How to tell? Make a plan.
- What you will say? Practice with client.
- What will you say or do if...?
- If there is a risk of violence, discuss whether or not to disclose, or how to disclose with counsellor or friend present.

Family Planning: A Global Handbook for Providers



- Reference guide for family planning providers & summarizes WHO family planning guidance
- Launched in October 2007, updated in 2011
- Soon to be updated in 2016 (incorporating new WHO guidance on multiple SRH topics)
- by the INFO Project at the Johns Hopkins Bloomberg School of Public Health. Endorsed by nearly 50 organizations



Contents: Method chapters

- Combined oral contraceptives (COCs)
 - Patch
 - Vaginal Ring
- Combined injectable contraceptives (CICs)
- Emergency contraceptive pills
- Progestogen-only pills
- Progestogen-only injectables
- Implants
- Copper-bearing IUD
 - LNG-IUD

- Vasectomy
- Female sterilization
- Lactational amenorrhea method
- Fertility awareness-based methods
 - Withdrawal
- Condom
- Female condom
- Spermicides/diaphragm



Chapter Headings

- Key points
- Helping the Client Decide about Combined Oral Contraceptives (COCs)
- Side effects, health benefits, and risks
 - COCs and cancer
- Who can and cannot use combined oral contraceptives
 - Medical eligibility criteria
- Providing combined oral contraceptives
- Following up users of combined oral contraceptives
- Questions and Answers



Progestin-Only Injectables

Key Points for Providers and Clients

- Bleeding changes are common but not harmful. Typically, irregular bleeding for the first several months and then no monthly bleeding.
- Return for injections regularly. Coming back every 3 months (13 weeks) for DMPA or every 2 months for NET-EN is important for greatest effectiveness.
- Injection can be as much as 2 weeks early or late. Client should come back even if later.
- Gradual weight gain is common.
- Return of fertility is often delayed. It takes several months longer on average to become pregnant after stopping progestinonly injectables than after other methods.

What Are Progestin-Only Injectables?

- The injectable contraceptives depot medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN) each contain a progestin like the natural hormone progesterone in a woman's body. (In contrast, monthly injectables contain both estrogen and progestin. See Monthly Injectables, p. 81.)
- Do not contain estrogen, and so can be used throughout breastfeeding and by women who cannot use methods with estrogen.
- DMPA, the most widely used progestin-only injectable, is also known as "the shot," "the jab," the injection, Depo, Depo-Provera, Megestron, and Petogen.
- NET-EN is also known as norethindrone enanthate, Noristerat, and Syngestal. (See Comparing Injectables, p. 359, for differences between DMPA and NET-EN.)

Progestin-Only Injectables 59





 Given by injection into the muscle (intramuscular injection). The hormone is then released slowly into the bloodstream. A different formulation of DMPA can be injected just under the skin (subcutaneous injection). See New Formulation of DMPA, p. 63.

More

Less

effective

 Work primarily by preventing the release of eggs from the ovaries (ovulation).

How Effective?

Effectiveness depends on getting injections regularly: Risk of pregnancy is greatest when a woman misses an injection.

- As commonly used, about 3 pregnancies per 100 women using progestin-only injectables over the first year. This means that 97 of every 100 women using injectables will not become pregnant.
- When women have injections on time, less than 1 pregnancy per 100 women using progestin-only injectables over the first year (3 per 1,000 women).

Return of fertility after injections are stopped: An average of about 4 months longer for DMPA and 1 month longer for NET-EN than with most other methods (see Question 7, p. 79).

Protection against sexually transmitted infections (STIs): None

Family Planning: A Global Handbook for Providers

Side Effects, Health Benefits, and Health Risks

Side Effects (see Managing Any Problems, p. 75)

Some users report the following:

- Changes in bleeding patterns including, with DMPA:
 - First 3 months:
 - Irregular bleeding
 - Prolonged bleeding
 - At one year:
 - No monthly bleeding
 - Infrequent bleeding
 - Irregular bleeding
- NET-EN affects bleeding patterns less than DMPA. NET-EN users have fewer days of bleeding in the first 6 months and are less likely to have no monthly bleeding after one year than DMPA users.
- Weight gain (see Question 4, p. 78)
- Headaches
- Dizziness
- · Abdominal bloating and discomfort
- Mood changes
- Less sex drive

Other possible physical changes:

Loss of bone density (see Question 10, p. 80)

Why Some Women Say They Like Progestin-Only Injectables

- Do not require daily action
- Do not interfere with sex
- Are private: No one else can tell that a woman is using contraception
- · Cause no monthly bleeding (for many women)
- · May help women to gain weight



Progestin-Only Injectables 61





Known Health Benefits

DMPA

Helps protect against:

- · Risks of pregnancy
- Cancer of the lining of the uterus (endometrial cancer)
- Uterine fibroids

May help protect against:

- Symptomatic pelvic inflammatory disease
- Iron-deficiency anemia

Reduces:

- Sickle cell crises among women with sickle cell anemia
- Symptoms of endometriosis (pelvic pain, irregular bleeding)

NET-EN

Helps protect against:

Iron-deficiency anemia

None

Known Health Risks

None

NET-EN may offer many of the same health benefits as DMPA, but this list of benefits includes only those for which there is available research evidence.

Correcting Misunderstandings (see also Questions and Answers, p. 78)

Progestin-only injectables:

- Can stop monthly bleeding, but this is not harmful. It is similar to not
 having monthly bleeding during pregnancy. Blood is not building up
 inside the woman.
- Do not disrupt an existing pregnancy.
- Do not make women infertile.


62 Family Planning: A Global Handbook for Providers

New Formulation of DMPA

A formulation of DMPA has been developed specifically for injection into the tissue just under the skin (subcutaneously). This new formulation must be delivered by subcutaneous injection. It will not be completely effective if injected in other ways. (Likewise, DMPA for injection into the muscle must not be injected subcutaneously.)

The hormonal dose of the new subcutaneous formulation (DMPA-SC) is 30% less than for DMPA formulated for injection into the muscle—104 mg instead of 150 mg. Thus, it may cause fewer side effects, such as weight gain. Contraceptive effectiveness is similar. Like users of intramuscular DMPA, users of DMPA-SC have an injection every 3 months.

DMPA-SC will be available in prefilled syringes, including the single-use Uniject system. These prefilled syringes will have special short needles meant for subcutaneous injection. With these syringes, women could inject DMPA themselves. DMPA-SC was approved by the United States Food and Drug Administration in December 2004 under the name "depo-subQ provera 104." It has since also been approved in the United Kingdom.



THE AN





New Problems That May Require Switching Methods

May or may not be due to the method.

Migraine headaches (see Identifying Migraine Headaches and Auras, p. 368)

- . If she has migraine headaches without aura, she can continue to use the method if she wishes.
- If she has migraine aura, do not give the injection. Help her choose a method without hormones.

Unexplained vaginal bleeding (that suggests a medical condition not related to the method)

Progestin-Only Injectables

- Refer or evaluate by history and pelvic examination. Diagnose and treat
- If no cause of bleeding can be found, consider stopping progestin-only injectables to make diagnosis easier. Provide another method of her choice to use until the condition is evaluated and treated (not implants or a copper-bearing or hormonal IUD).
- If bleeding is caused by sexually transmitted infection or pelvic inflammatory disease, she can continue using progestin-only injectables during treatment.

Certain serious health conditions (suspected blocked or narrowed arteries, liver disease, severe high blood pressure, blood clots in deep veins of legs or lungs, stroke, breast cancer, or damage to arteries, vision, kidneys, or nervous system caused by diabetes). See Signs and Symptoms of Serious Health Conditions, p. 320.

- Do not give next injection.
- Give her a backup method to use until the condition is evaluated.
- Refer for diagnosis and care if not already under care.

Suspected pregnancy

- Assess for pregnancy.
- Stop injections if pregnancy is confirmed.
- There are no known risks to a fetus conceived while a woman is using injectables (see Question 11, p. 80).

Helping Continuing Users of Progestin-Only Injectables 77

Questions and Answers About **Progestin-Only Injectables**

1. Can women who could get sexually transmitted infections (STIs) use progestin-only injectables?

Yes. Women at risk for STIs can use progestin-only injectables. The few studies available have found that women using DMPA were more likely to acquire chlamydia than women not using hormonal contraception. The reason for this difference is not known. There are few studies available on use of NET-EN and STIs. Like anyone else at risk for STIs, a user of progestin-only injectables who may be at risk for STIs should be advised to use condoms correctly every time she has sex. Consistent and correct condom use will reduce her risk of becoming infected if she is exposed to an STI.

2. If a woman does not have monthly bleeding while using progestin-only injectables, does this mean that she is pregnant?

Probably not, especially if she is breastfeeding. Eventually most women using progestin-only injectables will not have monthly bleeding. If she has been getting her injections on time, she is probably not pregnant and can keep using injectables. If she is still worried after being reassured, she can be offered a pregnancy test, if available, or referred for one. If not having monthly bleeding bothers her, switching to another method may help.

3. Can a woman who is breastfeeding safely use progestin-only injectables?

Yes. This is a good choice for a breastfeeding mother who wants a hormonal method. Progestin-only injectables are safe for both the mother and the baby starting as early as 6 weeks after childbirth. They do not affect milk production.

4. How much weight do women gain when they use progestin-only injectables?

Women gain an average of 1-2 kg per year when using DMPA. Some of the weight increase may be the usual weight gain as people age. Some women, particularly overweight adolescents, have gained much more than 1-2 kg per year. At the same time, some users of progestin-only injectables lose weight or have no significant change in weight. Asian women in particular do not tend to gain weight when using DMPA.

5. Do DMPA and NET-EN cause abortion?

No. Research on progestin-only injectables finds that they do not disrupt an existing pregnancy. They should not be used to try to cause an abortion. They will not do so.

Family Planning: A Global Handbook for Providers



For further information http://www.who.int/reproductivehealth/en/ Tweet to @HRPresearch





